A phase 1 study of nilotinib in combination with paclitaxel in patients with advanced solid tumors.

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-03-19 DOI:10.1158/1078-0432.CCR-24-3049

Sarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, Sarah B Miller, Barry C Johnson, Larry Anderson, Larry Rubinstein, Brandon Miller, Deborah F Wilsker, Katherine V Ferry-Galow, Richard Piekarz, Jennifer Zlott, Murielle Hogu, Lamin Juwara, Julia Krushkal, Mariam Konaté, Alida Palmisano, Yingdong Zhao, Jerry Collins, Ralph E Parchment, James H Doroshow, Alice P Chen

{"title":"A phase 1 study of nilotinib in combination with paclitaxel in patients with advanced solid tumors.","authors":"Sarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, Sarah B Miller, Barry C Johnson, Larry Anderson, Larry Rubinstein, Brandon Miller, Deborah F Wilsker, Katherine V Ferry-Galow, Richard Piekarz, Jennifer Zlott, Murielle Hogu, Lamin Juwara, Julia Krushkal, Mariam Konaté, Alida Palmisano, Yingdong Zhao, Jerry Collins, Ralph E Parchment, James H Doroshow, Alice P Chen","doi":"10.1158/1078-0432.CCR-24-3049","DOIUrl":null,"url":null,"abstract":"Purpose: We assessed the safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), efficacy, pharmacokinetic, and pharmacodynamics of the nilotinib-paclitaxel combination in 44 patients with solid tumors.Patients and methods: Paclitaxel was administered intravenously (days 1, 8, and 15) and nilotinib was administered twice daily orally beginning on cycle 1 day 2 (C1D2, escalation) or C1D3 (expansion) in 28-day cycles using a 3+3 dose escalation design. Pharmacodynamic biomarkers of drug action were assessed in paired tumor biopsies and circulating tumor cells (CTCs) at the RP2D.Results: The RP2D was 300 mg nilotinib twice daily with 80 mg/m2 paclitaxel. Grade 4 (Gr4) neutropenia and Gr3 rash, photosensitivity, and transaminase elevation were dose-limiting. The most common Gr3-4 toxicities were hematological and hypophosphatemia; 1 patient (2%) experienced Gr3 peripheral neuropathy. Three patients (2 with adult ovarian granulosa cell tumors [AOGCT] and 1 with endometrial carcinoma) had confirmed partial responses (cPR); the patients with AOGCT remained on study for 5 and 6+ years and mesenchymal-like CTCs were measured prior to progression or during treatment holiday (patients 12 and 10, respectively).Conclusions: This study determined the MTD of this combination, demonstrated sustained cPRs in patients with AOGCT, and profiled molecular pharmacodynamic responses that will inform further mechanism of action studies. The rate of peripheral neuropathy suggests enhanced tolerability of this combination.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":""},"PeriodicalIF":10.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.CCR-24-3049","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We assessed the safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), efficacy, pharmacokinetic, and pharmacodynamics of the nilotinib-paclitaxel combination in 44 patients with solid tumors.

Patients and methods: Paclitaxel was administered intravenously (days 1, 8, and 15) and nilotinib was administered twice daily orally beginning on cycle 1 day 2 (C1D2, escalation) or C1D3 (expansion) in 28-day cycles using a 3+3 dose escalation design. Pharmacodynamic biomarkers of drug action were assessed in paired tumor biopsies and circulating tumor cells (CTCs) at the RP2D.

Results: The RP2D was 300 mg nilotinib twice daily with 80 mg/m2 paclitaxel. Grade 4 (Gr4) neutropenia and Gr3 rash, photosensitivity, and transaminase elevation were dose-limiting. The most common Gr3-4 toxicities were hematological and hypophosphatemia; 1 patient (2%) experienced Gr3 peripheral neuropathy. Three patients (2 with adult ovarian granulosa cell tumors [AOGCT] and 1 with endometrial carcinoma) had confirmed partial responses (cPR); the patients with AOGCT remained on study for 5 and 6+ years and mesenchymal-like CTCs were measured prior to progression or during treatment holiday (patients 12 and 10, respectively).

Conclusions: This study determined the MTD of this combination, demonstrated sustained cPRs in patients with AOGCT, and profiled molecular pharmacodynamic responses that will inform further mechanism of action studies. The rate of peripheral neuropathy suggests enhanced tolerability of this combination.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.